1656 E. Mabel St., PO Box 24-5218, Tucson, AZ 85724, USA.
Curr Pharm Des. 2013;19(34):6218-25. doi: 10.2174/1381612811319340013.
While the chemotherapeutic effect of curcumin, one of three major curcuminoids derived from turmeric, has been reported, largely unexplored are the effects of complex turmeric extracts more analogous to traditional medicinal preparations, as well as the relative importance of the three curcuminoids and their metabolites as anti-cancer agents. These studies document the pharmacodynamic effects of chemically-complex turmeric extracts relative to curcuminoids on human breast cancer cell growth and tumor cell secretion of parathyroid hormone-related protein (PTHrP), an important driver of cancer bone metastasis. Finally, relative effects of structurallyrelated metabolites of curcuminoids were assessed on the same endpoints. We report that 3 curcuminoid-containing turmeric extracts differing with respect to the inclusion of additional naturally occurring chemicals (essential oils and/or polar compounds) were equipotent in inhibiting human breast cancer MDA-MB-231 cell growth (IC50=10-16µg/mL) and secretion of osteolytic PTHrP (IC50=2-3µg/mL) when concentrations were normalized to curcuminoid content. Moreover, these effects were curcuminoid-specific, as botanically-related gingerol containing extracts had no effect. While curcumin and bis-demethoxycurcumin were equipotent to each other and to the naturally occurring curcuminoid mixture (IC50=58µM), demethoxycurcumin did not have any effect on cell growth. However, each of the individual curcuminoids inhibited PTHrP secretion (IC50=22-31µM) to the same degree as the curcuminoid mixture (IC50=16µM). Degradative curcuminoid metabolites (vanillin and ferulic acid) did not inhibit cell growth or PTHrP, while reduced metabolites (tetrahydrocurcuminoids) had inhibitory effects on cell growth and PTHrP secretion but only at concentrations ≥10-fold higher than the curcuminoids. These studies emphasize the structural and biological importance of curcuminoids in the anti-breast cancer effects of turmeric and contradict recent assertions that certain of the curcuminoid metabolites studied here mediate these anti-cancer effects.
虽然姜黄素(三种主要姜黄素之一,源自姜黄)的化学治疗效果已被报道,但对于更类似于传统药物制剂的复杂姜黄提取物的效果以及三种姜黄素及其代谢物作为抗癌剂的相对重要性,仍有大量未被探索。这些研究记录了与姜黄素相比,化学上复杂的姜黄提取物对人乳腺癌细胞生长和肿瘤细胞甲状旁腺激素相关蛋白(PTHrP)分泌的药效学影响,PTHrP 是癌症骨转移的重要驱动因素。最后,还评估了结构相关姜黄素代谢物对相同终点的相对影响。我们报告说,三种含姜黄素的姜黄提取物在包含其他天然存在的化学物质(精油和/或极性化合物)方面存在差异,当浓度根据姜黄素含量归一化时,它们在抑制人乳腺癌 MDA-MB-231 细胞生长(IC50=10-16μg/mL)和骨溶解 PTHrP 分泌(IC50=2-3μg/mL)方面具有同等效力(IC50=10-16μg/mL)。此外,这些作用是姜黄素特有的,因为植物相关的姜酚提取物没有作用。虽然姜黄素和双去甲氧基姜黄素彼此等效,并且与天然存在的姜黄素混合物等效(IC50=58μM),但去甲氧基姜黄素对细胞生长没有任何影响。然而,每种单独的姜黄素都抑制了 PTHrP 分泌(IC50=22-31μM),与姜黄素混合物的程度相同(IC50=16μM)。降解的姜黄素代谢物(香草醛和阿魏酸)不会抑制细胞生长或 PTHrP,而还原的代谢物(四氢姜黄素)对细胞生长和 PTHrP 分泌具有抑制作用,但仅在浓度比姜黄素高 10 倍以上时才具有抑制作用。这些研究强调了姜黄素类化合物在姜黄抗乳腺癌作用中的结构和生物学重要性,并反驳了最近的断言,即研究中某些姜黄素代谢物介导了这些抗癌作用。